All Your Vitals At Home With One Device

Sathya Elumalai, Founder and CEO of Aidar Health, wants to make using his simple device part of your daily routine, like brushing your teeth, as a preventative measure in health, even if you don’t live with a chronic health condition.

For those that do, it can be a lifesaver. Even if you’re healthy it can be a lifesaver by detecting something early. We’ve all known otherwise healthy people who have a heart attack, stroke or even get diagnosed with cancer at a late stage.

Early detection still remains one of the best ways to prevent a fatal diagnosis.

The device called MouthLab is the first 30-second non-invasive, tricorder-style handheld device to record all your vitals.

You can use it within the comfort of your own home without the need of other devices.

“Although half of the US population have chronic conditions, the problem is, everyone is subject to multiple chronic conditions. Providing only what is essential for your one condition, is not going to really help you. Every year, patients develop other conditions.”

-Sathya Elumalai

Sathya learned this first-hand from his own experience with his Mom.

“My mom suffers from multiple chronic conditions. It started off with diabetes, and then moved on to heart condition, and then, all other complications associated with it. So, what MouthLab can do is help you predict complications early.” -SATHYA

MouthLab measure all these different parameters each day, so if you find something wrong, it can be detected early.

“Let’s say you’re diabetic, but if you see some problems within your heart condition, like blood pressure or or heart rate, that can be captured at a very early stage.” -SATHYA

It not only helps patients, but helps providers take care of patients at an early stage.

Specifically, the MouthLab device measures:

Your Temperature

Your Blood Pressure

Your ECG

Your Blood Oxygen Saturation

Your Pulse Rate

Your Breathing Rate and Pattern

Your Lung Function lung function (technically called FEV1. FEV1 or FVC)

And soon…Your Dehydration Level and Glucose

    Sathya Elumalai, MS, MBA, Founder and CEO of Adair Health, is a medical device executive with over 15 years of experience working with payers, providers, pharmaceutical companies, and patients. At Multisensor Diagnostics (MDx), Elumalai has developed a revolutionary tricorder-style rapid medical assessment device and artificial intelligence-enabled triaging system for efficient home management of chronic disease.

In addition to his efforts at MDx, Elumalai also serves as an advisory board member at Rutgers University, as a PCORI Ambassador, and PCORI merit reviewer. Elumalai holds a dual master’s degree in public health and healthcare management from Johns Hopkins University.

He is also a certified professional in healthcare quality and safety with over 10 years of diverse leadership experience at the Johns Hopkins Medical Institute. Elumalai is a proven leader recognized for building scalable processes, integrating analytics into decision making, improving customer satisfaction, and driving large-scale digital transformations in health care.

FOR MORE INFORMATION VISIT: http://www.aidar.com

 

LIKE and FOLLOW the BOLDTV page on Facebook to view

Maria Dorfner’s interview with Sathya Elumalai

 

 BoldTVHealth

LINK TO BOLDTV PAGE: https://www.facebook.com/BoldTV/

 

bold1


BABO Takes On Consumable Paper Industry

Meet the ONLY company IN THE WORLD that produces a consumable paper product.

It’s made with 100% bamboo and no other ingredient.

It’s so pure BABO salespeople in China actually eat it to demonstrate how pure it is.

And BABO owns the forest where the bamboo is grown.

The beauty is once all their products are developed, they all return to the planet…

In its natural, original form.

There is only one byproduct from manufacturing process; fed back into their koi pond.

 

There are a few competitors that CLAIM to be bamboo, but in fact are produced with other bi-products, such as sugarcane that binds the paper together.

Some only use 20% bamboo products.

We sat down with the co-founders of BABO, Paul Ruitenberg and Gustavo Andres Avila at the BOLDTV studios to learn more.

How was the company BABO started?

The company was started by a bold woman in China, who went against the grain, pun intended, of all other companies in China, insisting she wanted to make paper out of bamboo, with no other ingredients.

After years of research, BABO was born.

What makes the bamboo in BABO’s products unique?

Bamboo Quinone is an anti-bacterial compound in bamboo, and it’s only part of what makes their bamboo products special.

Bamboo itself dates back 7,000 years in China. It symbolizes virtue, Oriental beauty, and natures connection to humans.

Bamboo is actually stronger than brick, wood and concrete.

Wow, what other products do you have?

We also have baby wipes. Many babies get rashes from the chemicals in the wipes. On BOLDTV, we talk about how when people get a cold, they think the redness around their nose is caused by rubbing. It’s actually caused by the trace amounts of bleach used in regular tissue paper to make it white.

Interesting. Most people probably think the redness IS because of their cold or from the rubbing. Your BABO tissues do not do that?

Using our bamboo made tissue, bath tissue, paper towels and baby wipes assures no chemicals, no skin irritation, no rash and no bleach. And again, we’re the only bamboo made product in the world with 100% bamboo.

Awesome. What are other benefits of using bamboo?

  • No particle dust when used
  • Perfect for sensitive skin and allergies
  • Can be used as a wet tissue
  • All-natural, chemical-free scent
  • Naturally anti-viral and anti-bacterial
  • No residue when wet
  • Strength of the paper
  • Degradable in water
  • Bamboo fiber, uncolored paper
  • Does not contain any florescent agents
  • Most eco-friendly household product on the market
  • Does not contain any bleaching
  • Environmentally-friendly
  • Perfect consistency

“We at BABO want to provide the world with a 100% sustainable product leaving no traces of dyes, chemicals or bi-products on the earth.” -Paul Ruitenberg, co-founder, BABO

“That is why we use only 100% unbleached bamboo to manufacture our bamboo products, nothing else. It’s taken years of research, hard work and trial and error to provide a luxury product that has no other ingredients, but we think our planet is worth it.” -Gustavo Andres Avila, co-founder, BABO

 

We do too. Wonderful for health-conscious consumers, who care about the planet. Thank you for joining us!

Where can people, schools, hospitals and hotels obtain this?

 https://www.BABOUS.com

Be sure to Like and Subscribe to the BOLDTV page on FACEBOOK to get an instant notification of when their interview is LIVE! 

 #BOLDTV

We educate and empower people on how to live healthier, longer lives.

 

cropped-logonewsmd
NewsMD Communications

Have a story? Contact: maria.dorfner@yahoo.com

Stay Healthy: Avoid Cancer Causing Glyphosate

  • glyphosate in food

Bayer to Invest Billions in “Safe” Weedkillers.

 

Messinas is the global maker of Pulverize, the only safe, tested and trusted weedkiller.
Contact: james@messinas.com

One Day After We Post about Pulverize, a safe alternative to Roundup. 

messina5

We spoke to James Messina following Bayer’s announcement today and he had this to say:

“Speaking for a company who’s already selling an effective weed killer line that uses ingredients found in nature and others that are approved for organic gardening, with availability in more than 8,000 retailers in all 50 states, we are flattered to see that big companies are taking notice of the blueprint we’re laying out.”

“While Bayer takes years to reinvent the wheel, we want consumers to know that PULVERIZE Weed Killers are available today to provide an alternative to the active ingredient glyphosate found in products like Roundup and others.  While we may not have their advertising budget, there is a family standing behind these products ready to meet the groundswell of change the public is demanding for effective alternatives, and we’re excited at the brand we’re delivering.” – CEO of Messinas, James Messina

FOLLOWUP INTERVIEW with James Messina, CEO, Messinas:

When did you learn about Bayer’s announcement to invest $5.6B in an alternative, safe weed killer?  

JAMES MESSINA: Laying in bed this morning.  I was scrolling through the news and sent my team a text of the article screenshot at 5:58 am.

What was your initial reaction to the news? 

JAMES MESSINA: I laughed and thought, “I can just see the headline now…’NEW FROM THE MAKERS OF GLYPHOSATE!’  It’s a poorly vailed attempt at righting the ship.

 

What else do you think about it?

JAMES MESSINA: Personally I don’t think change ever comes from those in power; not governments, not companies…there’s no incentive for those who are in power to change the status quo.  They have everything to loose. 

I think this is a PR move meant to address the continued assault on their company, their products and their stock price.  I think they’ve blown this so bad that the only thing left is for them to get out of it and get back to their core business with a fund set up for the lawsuits…other than that, I just don’t see a way for them to regain the public’s trust. 

 

Why would they start from scratch rather than acquire a trusted brand like yours already in existence, even if you wouldn’t sell? Announcement says development would take years. Makes no sense. 

JAMES MESSINA: It makes perfect sense if you know anything about ego.  I’ve dealt with this before.  Big companies feel like this: with all of our resources and all of our expertise and all of our MONEY, how can we not find this solution internally?! 

Why on earth should we pay 100x when we can do it for 10x?  BOr worse, they think let’s steal this idea and make them sue us.  They’ll run out of money fighting us before they could ever beat us.  

Again, I’ve seen this, I’ve lived this, and I’ve fought against these types.  Corporate folks who spend their whole lives in big companies have no appreciation for the work small companies do.  They don’t understand our motivation. 

If you’re making a great living in a machine, you don’t believe small company people who work overtime without overtime pay.  You don’t think a guy in his garage can be better than a million dollar lab.  It’s like they speak a completely different language.

Is Bayer aware of your product? Have you made them aware of it? 

JAMES MESSINA: Oh yeah…check this out.  In May of 2018, we got an order through our website from someone at MONSANTO!  They used their work email and had the PULVERIZE product sent to their corporate offices.  Seeing this, I sent them a letter with it:

MONSANTO
Attn: Dan Wright / Paul Ratliff
800 N Lindberg Blvd, Q220
Saint Louis, MO 63167

RE: ORDER NUMBER 10126 FOR PULVERIZE WEED & GRASS KILLER

Dan/Paul,

I wasn’t sure who to address this to, as both of your names were on the order that was forwarded to me, but I wanted to personally thank you both for your interest in Messinas Pulverize® Weed & Grass Killer.

Should either of you or others at Monsanto wish to connect and discuss these products or other Messinas items, please let me know.I would be happy to make myself available.

All my best,

James Messina
President

Dan Wright is a Senior Science Fellow at Bayer

Paul Ratliff is Product Development Manager at Monsanto

 

What is the date of that letter?

JAMES MESSINA:  Recent. May 10, 2018

So, Monsanto is aware of you. Did they place an order with you?

JAMES MESSINA: Yes! They ordered two bottles of Pulverize on May 9th, 2018 at exactly 11:05 a.m. and we sent them the products.

Wow. What do you think their motives were? Stealing your secret sauce *laughter*?

JAMES MESSINA: I think they became aware of the product and wanted to evaluate how well it worked. I think they also wanted to send a message to use that we are on their radar. That’s why I sent a note back –to let them know I’m aware and am not going away.

Let me ask you, based on everything we now know about Roundup –do you think there is anything Bayer can do to get back in the public’s good graces? Clearly, the public isn’t buying their announcement today as being a genuine concern for their health and safety.

JAMES MESSINA: I believe that trust is something that is very hard to rebuild for big companies, especially when their motivation comes into question.  Had Bayer acted before the first lawsuit in the US, when countries in Asia and Europe started to question the product’s safety, it would have felt different. 

Had Bayer moved to re-evaluate the claims of Roundup, or release a statement about their interest in finding organic alternatives, before a jury awarded a couple in California damages in excess of $2,000,000,000, it would have felt different.  But they didn’t. 

They came out after more than $2.25 billion dollars in damages were awarded in three trials, after more than 13,000 other law suits are still yet to be decided and after multiple countries restricted and/or banned the sale of their product. 

It would appear that their motivation may not be as altruistic as people would wish it to be; appearing to be motivated by a stock price that has wiped 45% of their value off the books.

What’s most interesting is that this issue was not Bayer’s problem, originally; it wasn’t until they purchased Monsanto, the maker of glyphosate and Roundup’s trademarks.  They brought this fox into their henhouse, and it’s been a problem since the very beginning.

Thank you for your time.

You can view Health Correspondent, Maria Dorfner‘s full interview with Messina on BOLDTV

https://www.facebook.com/BoldTV/

Photo Courtesy: ASCHA STEINBACH/SHUTTERSTOCK / Farmer sprays crops in Germany.

Bayer AG BAYRY -1.53% plans to invest €5 billion ($5.64 billion) on developing new ways to combat weeds over the next decade, as the German chemicals and pharmaceuticals giant seeks to win back trust in its business in the wake of thousands of lawsuits alleging its Roundup herbicide causes cancer.

A big legal fight over the blockbuster weedkiller—inherited with its takeover of Monsanto Co. last year—has plunged Bayer into one of the worst crises in its 155-year history. The company has lost the first three jury trials to plaintiffs claiming Roundup gave them non-Hodgkin lymphoma, with the highest award topping $2 billion. In response, its shares have almost halved over the past year.

FOR THE REST OF THIS ARTICLE visit The Wall Street Journal at: https://www.wsj.com/articles/bayer-to-invest-billions-in-weedkillers-in-wake-of-roundup-controversy-11560514273

selective focus photography of white petaled flower
Photo by Ylanite Koppens on Pexels.com

BREAKING NEWS today. Bayer announced it will spend $5.6 Billion to create a safe, organic weed killer. It will take years to reach market.

“My two cents: My question to Bayer is why the need to develop your own when one (Pulverize by Messinas) already exists? Do you really care about people’s health or is this about caring about your own image and profits?

I have to say this reminds me of Coca-Cola getting into the water business ONLY after sales for a healthy alternative to toxic soda exceeded sales of soda. The public then learned their water was tap water.

When brands can’t be trusted to put people before profits –people really need to be careful, especially when it comes to health. You can’t replace or buy that back once damaged.”

-Maria Dorfner, CEO, NewsMD

Here’s all you need to know about glyphosate, the main chemical ingredient in Roundup, that is now infiltrating our food. LiveLoveFruit did extensive research to uncover where it’s hiding.

Once you read this check your pantry at home and make healthier choices now that you know. If you want to keep yourself, your family and children healthy know the facts.

Let’s face it TV segments are 2 to 5 minutes tops, so you’re not getting all you need to know in one place. Roundup was first registered in the United States in 1974. We’ve all been exposed to it.

New York City parks and playgrounds use it. When we’re out nature thinking we’re doing something healthy –we’re unknowingly being exposed to toxins. Now that all government official know and all consumers know and The World Health Organization has deemed Roundup toxic –sales of it need to STOP.

SHAME on BAYER for making it a part of their portfolio. We will not stop until it is banned everywhere.

We are grateful to those lawmakers taking a stand. NYC Councilman Ben Kallos has introduced a bill to ban it in all New York City parks and playgrounds. We appreciate his efforts on behalf of public safety and health. It’s not just this generation that is harmed. Glyphosate has been proven to harm DNA that affects future generations. It’s poison.

We are also grateful for Mother’s Across America, who are taking an active stand against it. They continue to grow and will continue their mission of eradicating Roundup from store shelves –educating all consumers about it.

Updated June 13, 2019 to reflect latest EWG test results in late May.

Concern over glyphosate in food is on the rise after Monsanto was found guilty in covering up their cancer-causing product, Roundup. Monsanto has been under scrutiny ever since they were ordered to pay $289 million in damages to plaintiff, Dewayne Johnson.

Just after the first successful trial in taking down Monsanto, the Environmental Working Group (EWG) published a haunting reporton the levels of glyphosate in food. According to the independent laboratory tests commissioned by the EWG, popular oat cereals, oatmeal, granola and snack bars come with a heavy dose of the cancer-causing weedkiller, Roundup.

Why Should We Care About Glyphosate in Food?

Glyphosate is the main ingredient found in the popular weed-killer Roundup. Back in 2015, a famous study published by the International Agency for Research of Cancer (IARC) came to the conclusion that glyphosate is “probably carcinogenic to humans (1).”

The link between glyphosate and Non-Hodgkin’s lymphoma is particularly strong. One study, published in 2008 by Swedish researchers, found that exposure to glyphosate tripled the risk of a subtype of non-Hodgkin called small lymphocytic lymphoma (2).

Another study published in 2003 showed a suggestive link between glyphosate-based herbicide use and non-Hodgkin lymphoma. The more pesticides a subject used, the more non-Hodgkin lymphoma incidences increased. Subjects who used five or more of the nine pesticides were “twice as likely to be NHL cases than controls (3).”

Aside from cancer, glyphosate has been associated with a host of health issues, like kidney disease (3), reproductive problems (4), liver damage (5) and birth defects (6).

Glyphosate also interferes with the ability of a plant to uptake nutrients from the soil. Glyphosate, which is a patented chelating agent, binds with nutrients in the soil, and prevents plants from absorbing them. It also acts as an antibiotic (7), which can kill bacteria both in the soil, and our own guts (both of which are incredibly important for plant and human health).

Regardless of the evidence, Monsanto still states that “Glyphosate has a 40-year history of safe and effective use. In evaluations spanning those four decades, the overwhelming conclusion of experts worldwide, including the Environmental Protection Agency (EPA), has been that glyphosate can be used safely.” Despite the lawsuit, it seems Monsanto is still in denial.

Products and Brands Filled with Glyphosate

Aside from the EWG report on glyphosate in food, other companies have also done independent testing for glyphosate residues in everyday food products. In 2016, Food Democracy Now! and The Detox Project commissioned tests that found high levels of glyphosate in many American foods – even products that are certified organic or non-GMO.

Below is a complete list of foods that contain glyphosate residues. I’ve combined data from both the report EWG released, as well as the reports released from Food Democracy Now! and the group’s “Detox Project.”

glyphosate in food

EWG Report (source):

• Granola
Back to Nature Classic Granola
Quaker Simply Granola Oats, Honey, Raisins & Almonds
Back to Nature Banana Walnut Granola Clusters
Nature Valley Granola Protein Oats ‘n Honey
KIND Vanilla, Blueberry Clusters with Flax Seeds

• Instant Oats
– Giant Instant Oatmeal, Original Flavor
– Quaker Dinosaur Eggs, Brown Sugar, Instant Oatmeal
Umpqua Oats, Maple Pecan
Market Pantry Instant Oatmeal, Strawberries & Cream

• Oat Breakfast Cereal
Cheerios Toasted Whole Grain Oat Cereal
Lucky Charms
Barbara’s Multigrain Spoonfuls, Original, Cereal
Kellogg’s Cracklin’ Oat Bran oat cereal

• Snack Bars
KIND Oats & Honey with Toasted Coconut
Nature Valley Crunchy Granola Bars, Oats ‘n Honey
Quaker Chewy Chocolate Chip granola bar
Kellogg’s Nutrigrain Soft Baked Breakfast Bars, Strawberry

• Whole Oats
Quaker Steel Cut Oats
Quaker Old Fashioned Oats
Bob’s Red Mill Steel Cut Oats
Nature’s Path Organic Old Fashioned Organic Oats
Whole Foods Bulk Bin conventional rolled oats
Bob’s Red Mill Organic Old Fashioned Rolled Oats (4 samples tested)

EWG Second Report (source):

– Quaker Simply Granola Oats
– Quaker Instant Oatmeal Cinnamon & Spice
– Quaker Instant Oatmeal Apples & Cinnamon
– Quaker Real Medleys Super Grains Banana Walnut
– Quaker Overnight Oats Raisin Walnut & Honey Heaven
– Quaker Overnight Oats Unsweetened with Chia Seeds
– Quaker Oatmeal Squares Brown Sugar
– Quaker Oatmeal Squares Honey Nut
– Apple Cinnamon Cheerios
– Very Berry Cheerios
– Chocolate Cheerios
– Frosted Cheerios
– Fruity Cheerios
– Honey Nut Cheerios
– Cheerios Oat Crunch Cinnamon
– Quaker Chewy S’mores
– Quaker Chewy Peanut Butter Chocolate Chip
– Quaker Breakfast Squares Soft Baked Bars Peanut Butter
– Quaker Breakfast Flats Crispy Snack Bars Cranberry Almond

EWG Third Report (source):

– Honey Nut Cheerios Medley Crunch
– Cheerios Toasted Whole Grain Oat Cereal
– Nature Valley Crunchy Granola Bars, Maple Brown Sugar
– Nature Valley Granola Cups, Almond Butter
– Chocolate Peanut Butter Cheerios
– Nature Valley Baked Oat Bites
– Nature Valley Crunchy Granola Bars, Oats and Honey
– Nature Valley Crunchy Granola Bars, Peanut Butter
– Nature Valley Granola Cups, Peanut Butter Chocolate
– Cheerios Oat Crunch Cinnamon
– Nature Valley Fruit & Nut Chewy Trail Mix Granola Bars, Dark Chocolate Cherry
– Nature Valley Granola Protein Oats n Dark Chocolate
– Multi Grain Cheerios
– Nature Valley Soft-Baked Oatmeal Squares, Blueberry
– Fiber One Oatmeal Raisin Soft-Baked Cookies
– Nature Valley Granola Peanut Butter Creamy & Crunchy
– Nature Valley Biscuits with Almond Butter
– Nature Valley Sweet & Salty Nut granola bars, Cashew
– Honey Nut Cheerios
– Nature Valley Soft-Baked Oatmeal Squares, Cinnamon Brown Sugar
– Nature Valley Fruit & Nut Chewy Trail Mix Granola Bars, Dark Chocolate & Nut

Moms Across America (source):

– Tropicana Orange Juice
– Minute Maid Orange Juice
– Stater Bros Orange Juice
– Signature Farms Orange Juice
– Kirkland Orange Juice

Food Democracy Now! and The Detox Project (source):

– Original Cheerios
– Honey Nut Cheerios
– Wheaties
– Trix
– Annie’s Gluten Free Bunny Cookies Cocoa & Vanilla
Kellog’s Corn Flakes
Kellog’s Raisin Bran
Kashi Organic Promise
Kellog’s Special K
Kellog’s Frosted Flakes
Cheez-It Original
Cheez-It Whole Grain
Kashi Soft Bake Cookies, Oatmeal, Dark Chocolate
Ritz Crackers
Triscuit Crackers
Oreo Original
Oreo Double Stuf Chocolate Sandwich Cookies
Oreo Double Stuf Golden Sandwich Cookies
Stacy’s Simply Naked Pita Chips (Frito-Lay)
Lay’s: Kettle Cooked Original
Doritos: Cool Ranch
Fritos (Original) (100% Whole Grain)
Goldfish crackers original (Pepperidge Farm)
Goldfish crackers colors
Goldfish crackers Whole Grain
Little Debbie Oatmeal Cream Pies
Oatmeal Cookies Gluten Free
365 Organic Golden Round Crackers
Back to Nature Crispy Cheddar Crackers

Mom’s Across America Wine Samples (Source):

– Gallo
– Beringer
– Mondavi
– Barefoot
– Sutter Home

U.S. PIRG Wine & Beer Samples (Source):

Wine
– Sutter Home Merlot
– Beringer Founders Estates Moscato
– Barefoot Cabernet Sauvignon
– Inkarri Malbec: Certified Organic
– Frey Organic Natural White

Beer
– Tsingtao Beer
– Coors Light
– Miller Lite
– Budweiser
– Corona Extra
– Heineken
– Guinness Draught
– Stella Artois
– Ace Perry Hard Cider
– Sierra Nevada Pale Ale
– New Belgium Fat Tire Amber Ale
– Sam Adams New England IPA
– Stella Artois Cidre
– Samuel Smith’s Organic Lager

Other Brands/Products and Miscellaneous:

– Ben & Jerry’s Ice Creams (source)
– Tampons (source)
– Non-organic cotton clothing products (source)
– Rainwater (source)
– Groundwater supplies (source)

How To Steer Clear of Glyphosate in Foods

Glyphosate contamination cannot be removed by washing (it is absorbed into the plant while it’s growing). It also is not broken down by cooking or baking.

In order to avoid glyphosate in food, follow the pointers below:

1. Always Look for Non-GMO Project Verified

If you’re purchasing a processed food item (that is, something boxed, bagged or canned), you can make sure it doesn’t contain GMO ingredients by looking for the Non-GMO Project Verified symbol (see below).

However, just because something is Non-GMO verified doesn’t mean that it isn’t necessarily clean of glyphosate. Glyphosate is a herbicide, and is sprayed on everything from wheats and oats to oranges and grapes.

The best way to ensure your products are GMO and glyphosate-free is to look for organic products with this Non-GMO verified label. That way, you know you’re eating a good product.

non-gmo project verified

2. Certified Organic is Better Than Non-Organic

By purchasing certified organic foods, you’ll be rest assured that your food doesn’t contain any glyphosate-containing chemicals.

Unfortunately, glyphosate use is so rampant, that some organic foods may contain small amounts of glyphosate residues.

Damaging herbicide drift can travel far, especially when it is applied in mornings when the spray gets hung up and moves with the air mass across fields (due to air temperature differences) (8).

Glyphosate also leaks into the watershed, which means it travels far, and can contaminate surrounding organic fields.

This is probably why Bob’s Red Mill Organic Oats were found with small levels of glyphosate residues. Their response to this?

“Because we at Bob’s Red Mill are dedicated to bringing all of our customers natural, healthy products, whether organic or conventional, we have inquired directly with farmers and with our suppliers to determine if glyphosate desiccation is used by the farmers supplying our products.

The majority of our conventional wheat is grown close to home in the Pacific Northwest where growing seasons are typically longer and the practice of desiccation is as such rarely used.

We’ve been told desiccation is not a practice used by our individual farmers. The growing, harvest and communal storage practices sometimes used by the wheat industry in general make it nearly impossible, however, for our multi-source suppliers to guarantee the practice of glyphosate desiccation is not used with all of the conventional wheat the suppliers sell to us.

We are able to assure our customers, however, that glyphosate desiccation is not a practice used for our organic products as the use of glyphosate is not permitted at any time in the cultivation of our organically grown ingredients. Our Customers who desire to be certain that glyphosate has not been used may wish to choose instead from our extensive line of certified organic products.” (source)

They then go on to state: “We are able to assure our customers, however, that glyphosate desiccation is not a practice used for our organic products, as the use of glyphosate is not permitted at any time in the cultivation of our organically grown ingredients. Our customers who desire to be certain that glyphosate has not been used may wish to choose instead from our extensive line of certified organic products.”

However, their organic products do contain glyphosate, as pointed out in the studies above. As a result, Bob’s Red Mill is facing a federal class action lawsuit.

The good news is that organic foods contain much lower levels of glyphosate compared to their conventional counterparts. This one example doesn’t mean that organic products are bad. Bob’s Red Mill didn’t take their standards seriously when it came to organic products, so all we can do is hope that other companies do.

3. Grow Your Own & Farmer’s Markets 

Another great way to ensure your food is grown glyphosate-free is by growing your own food (or sourcing it from farmers you trust at farmers’ markets). By growing your own food, you’ll feel more self-reliable, which is a super great feeling. You’ll also become more connected to the food you eat, as you’ll appreciate the time it took to grow that squash or tomato!

4. Look for Glyphosate Residue Free Labels

The Detox Project, a research and certification platform that uses an FDA-registered food-testing lab to test for toxic chemicals launched their own “Glyphosate Residue Free” label. This label offers more transparency and assures the purchaser that they’re not getting any glyphosate in the food they’re buying.

While these labels aren’t mainstream, the Detox Project is working with food manufacturers and grocery chains to get this label on more products.

About Author

Carly Fraser has her BSc (Hons.) Degree in Neuroscience, and is the owner and founder at Live Love Fruit. She currently lives in Winnipeg, Manitoba, with a determined life mission to help inspire and motivate individuals to critically think about what they put in their bodies and to find balance through nutrition and lifestyle. She has helped hundreds of thousands of individuals to re-connect with their bodies and learn self-love through proper eating habits and natural living. She loves to do yoga, dance, and immerse herself in nature.

RELATED ARTICLES: https://reason.com/2019/06/14/bayer-to-waste-5-6-billion-trying-to-appease-anti-pesticide-activists/

How much money does Monsanto make from Roundup?

In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits from herbicide products, mostly Roundup.

 

If that’s not enough, here are MORE foods owned by Monsanto:

https://feast.media/food-brands-owned-by-monsanto

Be sure to read:

“A Complete Guide to Roundup Exposure. Are You At Risk?”

https://www.yourgreenpal.com/blog/the-complete-guide-to-roundup-exposure-are-you-at-risk

HEALTH STORY? NEWS TIPS?

Contact: maria.dorfner@yahoo.com

NewsMD is a Division of Healthy Within Network

Sharing the Best in Consumer Health for Over Three Decades

“When We Tell Stories…People Listen.”

Messinas is the global maker of Pulverize, the only safe, tested and trusted weedkiller.
Contact: james@messinas.com

cbslogo

CBS THIS MORNING interviewed Dr. Agus, an oncologist for his expert opinion on glyphosate. Let’s just say it’s not a chemical he wants in his own body.

Dr. David Agus, a cancer specialist, joined “CBS This Morning” Thursday to sort out the claims. He says, “We just don’t know” exactly how glyphosate will impact the human body in the long run.

“The problem is when you eat something, say, glyphosate, there’s a 10, 20-year lag before disease and the intervention.”

Agus explains glyphosate emerged in the 1960s as a pipe cleaner, and then started being used as a weed killer. But in the 1990s, “usage went through the roof.”

When asked if he’d willingly put the chemical in his own body, Agus says he “certainly wouldn’t.”

Watch the complete interview with CBS THIS MORNING here:

https://www.cbsnews.com/news/what-you-need-to-know-about-glyphosate-the-cancer-linked-chemical-found-in-cheerios/

cbslogo1

 

About NewsMD: What’s Hot in Health

Maria Dorfner has been covering Medical/Health since 1993 after 10 years of working behind-the-scenes at major networks. She created, produced and co-hosted 7 half-hour health programs airing on CNBC, which she helped launch in 1989. Original programs include Healthcare Consumers co-hosted with Jay Michaels, Healthy Living, Lifestyles and Longevity and more.

She produced medical segments for NBC and NBC Miami, helped launch MedPage Today (sold to CNN), is the co-founder of The Cleveland Clinic News Service (CCNS) and the founder of NewsMD, a full-service production company specializing in health. She produced 21st Century Medicine for DISCOVERY and has been a trusted go-to source in health news for networks. She has also helped raised millions for non-profits and hospitals in need through volunteer work and working on capital campaigns.

She has travelled extensively interviewing a Who’s Who in Health and has produced successfully syndicated major talk shows. She was awarded a Medical Reporting Scholarship from the American Medical Association, won a Media Recognition Award from the American Heart Association, a Freddie Award for Excellence in Medical Reporting and more. She is in Who’s Who in American Women.

She is currently producing Late Night Health radio with host, Mark Alyn and an Executive Producer with NewsMD and AJA Creative Media, working alongside 4X Emmy-award-winning producer, Alex J. Aguiar. Please follow BOLDTV, founded by Carrie Sheffield, a co-production with Al Roker Productions, where Maria will be contribute health stories.

She is the author of 3 books. Healthy Within, PRESSure: Break Into Broadcasting and a family recipe cookbook called, Health Heart and Humor in an Italian-American Kitchen. Books are available on Amazon.

Maria began her career as an intern at NBC on the TODAY SHOW in 1983, while an undergraduate at Pace University, where she majored in English and Political Science. She served as Director of Communications for Ailes Communications, a political consulting firm and producer of programming. NBC awarded her a graduate scholarship to Columbia University. She was Miss Pace University and a Sigma Tau Delta National Honors student in English and a member of the Intercollegiate Model City Council in New York City.

Her lifelong mission in life is to educate and empower people to lead healthier lives.

This is her blog.

You can reach her at: maria.dorfner@yahoo.com

 

Face2Face Health: Concierge Care for Children

fit19
Children running

Face2Face Health is a web & mobile-based holistic pediatric telehealth platform with a mission to help parents and caregivers accurately learn about, identify, and manage their children’s health and well-being challenges –all in one simple place.

kiwitech5

Dr. Ami Shah, MD, FACP, FAARM
, founder of Face2Face Health is not only a physician for over two decades, but she’s also a Mom, who was frustrated when her own children were diagnosed with physical delays and she couldn’t easily find access to care or evidence-based information.

Shah says, “I was shocked as both a doctor and parent. The top three health websites had such outdated information. I couldn’t believe it. So much traffic means millions of parents are misinformed. I couldn’t even find another parent going through the same thing.  I wanted everything in one place. That’s when I took a step back to create a solution.”

wubba6

She realized parents, caregivers, and educators face the following fragmented approach to health and wellness:

CARE: Services are disconnected and not coordinated. Just 30% of 90M U.S. children are screened for challenges or receive timely and comprehensive care. Average wait time for a physician specialist can be 19 days & rural areas are underserved. One third must travel 40+ miles for care.

LEARN: According to the U.S. Dept of Health & Human Services, almost 90% of the population is health illiterate. Health and well-being information on several top websites is inaccurate, hard to find, incomplete and not reviewed by experts.

SHARE: Parents and caregivers feel isolated. Communities are needed that provide advocacy and support.

kidswater1

She’s not alone. 1 in 4 U.S. children have developmental, emotional, physical or learning issues and only 30% of all children are screened or have access to care, information and support.

AND the top 20 challenges in pediatrics cost our healthcare system $200B annually.

So she created Face2Face Health as a solution to offer people a complete digital wellness platform that allows access to multidisciplinary care via phone, video or concierge interactions; 200+ validated, evidence-based screening tools; 125+ peer-reviewed e-learning courses, and online support communities.

The Face2Face Health platform includes centralized Electronic Health Records (HIPAA, MU2, MU3, high tech). The EHR offers an integrative health approach covering over 70 traditional/alternative disciplines, SOAP forms, prescriptions, labs, remote monitoring, exercises, and other valuable resources.

This integrated hub streamlines clinical workflows and care coordination to expeditiously coordinate diagnoses, early intervention, comprehensive treatment, education, and optimized care.

It can be white-labeled, integrated, and adapted for different population segments & care conditions.

For many conditions, best patient outcomes can only be achieved through a coordinated, collaborative, comprehensive approach to care.

Surveys show parents & caretakers want expert-reviewed, trustworthy information in one place.

So if you’re seeking that one place, look no further than:

Face2Face Health at http://www.f2fhealth.com

On Twitter: @f2fhealth

Progress to date:User interface/user experience/product market fit: Questionnaire and phone survey of 500 multi-disciplinary providers and potential customers received over 85% product market offering support and guided site design. Developmental: Alpha tests and user experience feedback, each stage for optimizing product offering. We will be conducting beta testing with 500 to 1,000 parents and providers in Q4 2017, which has already been paid for as part of our UI/UX development. Pilots: we have partnered with a privately held company offering a B2C subscription testing service for children with over 500,000 parent subscribers and another organization involving both educators and parents. Competitive market gap analysis: Companies in the market offer limited services in comparison; few focus exclusively on pediatrics. Partners: We have partnered with a leading screening company and testing company.

E-Learning Development Progress:

1.Topic Identification

The use of Google Analytics drove selection of nearly 130 topics to be included in the Learning Module Development Series within Face2Face Health’s 5 (F2F) Knowledge Integrative silos:

a. General Health

b. Emotional Health

c. Development

d. Mind/Body/Nutrition

e. Education and Advocacy

2. Source Selection

Several top analytically driven consumer and professional websites were selected as information sources for each of the various topics, including:

a. Top medical literature and professional references

b. Popular referenced sites such as WebMD, Wikipedia

c. Reference databases such as PubMed and Google Scholar

3. Collection

Professional consultant researchers collected, referenced and tracked all relevant data to prepare for analysis of all available topic information.

4. Compare and Curate

Several subject matter experts compared and curated information to identify content reflecting the highest relevance, credibility and educational value.

5. Gap Analysis

To ensure comprehensiveness and quality control of our Learning Management System (LMS), global subject matter experts such as physicians, alterative health practitioners, developmental and educational experts further researched any gaps in integrative knowledge within the silos to guide further content collection as needed.

Transformation

The information was then transformed to original health-literate and referenced

copy materials.

7. Expert Review

Subject matter experts, including Advisory Board members representing expertise

across the 5 silos reviewed all modules for comprehension and accuracy.

8. Production Design and Development

Modules were then given to our design team for customized E-learning design

and development in collaboration with LMS consultant and content experts.

9. Delivery and Management

E-learning modules integration into the online LMS platform for interactive E-learning delivery and  management in process, including learning performance analyses and revisions and new content development as needed.

Face2Face Health Team:

Creator: Ami Shah

Education: Wright State University School of Medicine

Bio: Ami Anand Shah, MD FACP, FAARM is an entrepreneur, pharmaceutical industry executive, active part- time integrative medicine practitioner, philanthropist and leader in several local, state and national medical non-profit organizational communities.

She has over 15 years of both clinical practice and global versatile pharmaceutical industry executive experience with demonstrated leadership, people management and global expertise in the arenas of pharmacovigilance and risk management, clinical development, strategic business development/due diligence, global labeling, OTC/nutritionals formulation, clinical trial development and medical marketing from small sized to big sized pharmaceutical companies.

She is a Board Certified Internal Medicine physician and fellow of the American College of Physicians.

Board Certified in Integrative Medicine and also fellowship trained in Anti-aging, Regenerative and Functional Medicine, as well as Aesthetics.

She currently practices part-time Integrative, Personalized Medicine which focuses on integrative evidence based, peer reviewed holistic health, e consulting, physician health coaching, and telemedicine services for over 15 years.

Dr. Shah has held several leadership positions at the local, state and national levels (see Affliations section).

To date, she has mentored several next generational leaders, performs various free health care services in clinics or lectures in the community.

She has travelled to over 20 countries on medical missions.

Dr. Shah is also a member of countless other non-profit organizations too numerous to name but have in common a focus on children and women’s global health and education issues.

She has been the recipient of the prestigious top 50 Outstanding Asian Americans in business 2012.

She is also featured as one of the top 101 Indian American Emerging and Global Leaders by Roshni Media published in 2015.

Hospital Affiliation: ACP Fellow, NY Country Medical Society, SAHI, AAPI, Clinical Associate Prof, Wright State University

Title: Founder & CEO

Advanced Degree(s): MD FACP, FAARM

WARNING: LONG BIOS AHEAD!  About Team Members

Raj Jhaveri
Co-founder and Chief Technology Officer, MS

Biography:
Raj Jhaveri is an innovator, entrepreneur, social media persona, philanthropist, hip-hop dancer, and a former TV Host for Sony Entertainment Television and UrbanAsian.com.

He is known for his unique ways of charitable fundraising through entertainment and has been featured in multiple media outlets such as Entrepreneur Magazine, MTV, Vice Magazine – Motherboard, Wall Street Journal, Motley Fool, MedCity News and MedCrunch.

By day, Raj is a visionary entrepreneur and strategist in the Digital Health, Medical and Biotechnology Industry, who has worked with Bio-Reference Laboratories, Sage Science, Bio-Genex, Pfizer, Abpro Labs, Ferring Pharmaceuticals, Genentech and the Department of Defense in the past.

He obtained his Bachelor’s at Ohio State University and continued his graduate studies at Harvard Medical School. Later, he co-founded Manethryn Technology, Inc. and assisted in launching Fermentöme, Inc.

Raj is a partner at The Catalan Group, a strategy consulting firm based in New York. It successfully founded and launched Canopy Apps, a company focused on medical translation services and education with over 200,000 medical provider users.

He is also an in-house mentor at Techstars and, an industry consultant for General Catalyst Partners in regards to their healthcare investments.

In his spare time, he partakes in the fashion, film, music, and dance industry, and enjoys being a true “Curious George” exploring anything that is new and intriguing, hence his former social media persona as “The Urban Nerd.”

This allowed him to become the brand ambassador for a rising fashion brand, Convey.

Raj is also known for hosting The Annual Aquarius Charity Affair, an annual free event held in January/February, which has attracted and raised thousands multiple charities since 2008.

He is currently working on forming his first non-profit, The Urban Nerd Effect, where global causes and charities are conveyed through entertainment and free networking events.

Title:
Co-founder and Chief Technology Officer
Advanced Degree(s): MS
LinkedIn: https://www.linkedin.com/in/rajpjhaveri/

Dale McManis
Head of Education and Advocacy, BS, MEd, PHD

Biography:
Lilla Dale McManis is President and CEO of Parent in the Know and Early Childhood Research Solutions, launched to focus on assessment of the parental role and child functioning, and a consultant for numerous start-ups to improve and position products and services.

She holds a PhD in educational psychology with a concentration in learning and cognition, a master’s in special education, and a bachelor’s in child development.

She has taught special needs K-12 students in the public-school setting, served as Academic Coordinator and instructor for court-ordered teens in a non-traditional educational setting and as an instructor of prospective teachers at the University of Florida.

She has held senior research positions at the Massachusetts Department of Education as lead evaluator for the state’s school health programs and the Massachusetts Department of Public Health in the Division of Maternal and Child Health as Project Manager for the state’s school and adolescent programs and Co-Director of the Office of Statistics and Evaluation.

She was on the faculty at the University of Texas-Houston in the School of Public Health and then the Medical School-Developmental Pediatrics in the Children’s Learning Institute and the State Center for Early Childhood Development as part of multi-disciplinary teams on CDC, USDOE, and NIMH research grants.

She is the former Research Director for Hatch Early Learning, a leading technology content development company, where she was on the product development team and conducted product efficacy studies.

She is a founding member of the Early Childhood Technology Collaborative, has served as research consultant on a number of large projects, presented frequently at national conferences, & has published a number of academic papers.

She has been inducted into several honor societies: Golden Key, Phi Kappa Phi, & Phi Lambda Theta graduated summa cum laude, on the National Dean’s List, and received the Gamma Sigma Delta Outstanding Senior Award.

Title:
Head of Education and Advocacy
Advanced Degree(s): BS, MEd, PHD
LinkedIn: https://www.linkedin.com/in/dalemcmanisecars/

Doron Wesly
Chief Marketing Officer, BS

Biography:
Doron Wesly is Senior Vice President and Chief Marketing Officer for Lotame, where he spearheads global marketing, communications, and research and insights for a global team of data management specialists, enabling marketers, agencies, and publishers to harness audience data across all digital devices.

Prior to Lotame, Doron spent more than three years at Tremor Video (NYSE: TRMR) as head of Market Strategy, where he helped brand marketers understand the advertising impact of online video relative to all screens.

As online video expanded to more viewers and devices, Doron played a critical role in helping advertisers understand the advanced analytics emerging from these campaign, enhanced by his deep knowledge of cross-media studies, marketing mix models, attribution modelling, and more than 20 years of experience spanning traditional media planning to the frontiers of digital.

Prior to joining Tremor Video, Doron served as Senior Managing Partner, Managing Director, Leader Business Science and Planning, North America, for Mindshare, based in New York, where he led a multi-disciplined team that included consumer insights, competitive intelligence, digital analytics, business planning, and advanced analytics.

Doron’s marketing and research career has also included time as Global Media Director at Cheil Worldwide, Samsung’s in-house ad agency, based in Seoul, South Korea, and Millward Brown’s Strategic Services.

He spent time at the Interactive Advertising Bureau (IAB) leading industry research efforts, and he has worked for Terra Lycos, Interevco, and Hotbar.com. Doron is a citizen of both the Netherlands and Israel and is fluent in Dutch, Hebrew, and English.

He is also proficient in German and French and enough Korean (to be dangerous).

Doron speaks regularly on marketing and media topics at industry events and universities in the U.S., Europe, and Asia.

Title:
Chief Marketing Officer
Advanced Degree(s): BS
LinkedIn: https://www.linkedin.com/in/doronwesly/

Richard Hamilton
Head of Learning Management Systems, BA, MA

Biography:
Richard Hamilton is a veteran Communications Services provider experienced in Instructional Design, Sales and Marketing Communications and Multi-Media Production in corporate, agency, private business and independent markets.

His credits include pioneering effort in the development and implementation of many industry innovations involving computer-based learning, blended learning, distance learning, online interactive learning, online accredited Continuing Medical Education, Intranet portals, learning management systems, sale force automation and integrated marketing strategies.

As a consultant, Richard provided communication services to Affymax, Allergan, Amgen, Baxter Bioscience, Centocor, Genentech, Medicis, Neutrogena, Pharmacia, Roxro Pharma and Scios in the pharmaceutical industry and to Medical Communication firms Chandos Communications, Churchill Communications, HLS, IntraMed West, Pacific Communications and Triage Health Communications.

Prior to consulting, Richard held corporate positions as Training Media Producer, Sr. Instructional Designer, Communications Analyst and Product Marketing Manager at Syntex Laboratories; Distance Learning Manager and Corporate Multimedia and Information Development Manager at Applied Materials; and World-Wide Sales and Marketing Programs Development Manager for Sun Microsystems.

During his early career, while pursuing an education in Behavioral Sciences, Communication and Education Technology, Richard worked as a Community Worker, Training Media Producer and Rehabilitation Counselor for the Santa Clara County Department of Health.

Title:
Head of Learning Management Systems
Advanced Degree(s): BA, MA
LinkedIn: https://www.linkedin.com/in/rwhamilton/

Florence Michelet
Head of Medical Communications, MS, MBA

Biography:
Florence Michelet founded EosMorae, LLC in 2011, after more than 20 years of senior global and domestic US medical communications experience in major global corporations.

She has spent her entire career developing sound educational solutions for healthcare professionals (physicians, nurses, pharmacists, physician’s assistants, etc.) and patients in a variety of therapeutic areas.

A French native, Florence started her career in Paris as a statistician. After moving to the United States in 1989, she earned her MBA degree in international marketing and joined the field of strategic medical communications immediately thereafter.

In 1998, she joined Physicians World (a Thomson Reuters corporation), holding positions of increasing responsibility and ultimately being appointed as General Manager for GeoMed Global Communications, the company’s global division.

Florence moved to Oxford Clinical Communications (OCC) in 2004 as President of North American operations (including the global and US promotional medical education activities, and the Oxford Institute for Continuing Education, the CME-accredited division).

Prior to starting her own business, Florence was Senior Vice President, Director of Client Services, at Publicis Groupe Company for over 5 years, where she provided strategic leadership to a number of the company’s clients, both at the domestic and global level.

Title:
Head of Medical Communications
Advanced Degree(s): MS, MBA
LinkedIn: https://www.linkedin.com/in/florencemichelet/

Jennifer Kirschenbaum
General Counsel, BA, JD

Biography:
Jennifer Kirschenbaum is a managing partner of Kirschenbaum & Kirschenbaum, P.C.’s healthcare department.

She devotes her practice towards assisting practitioners in all aspects of private practice, Office-Based Surgery practice, Article 28 facility formation and operation, Independent Practice Association formation and operation and hospital based practice and hospital relationships/arrangements.

Jennifer began her career focusing on third party payor and government payor audit defense, OPMC and OPD licensure matters and general practice matters, including license agreements, during her time as an associate at Abrams Fensterman, et al.

Her practice expanded when she joined Rivkin Radler LLP, where she focused on regulatory compliance and transactional matters.

After bringing healthcare to Kirschenbaum and Kirschenbaum, P.C. in 2008, Jennifer has grown the firm’s healthcare department to representing over 800 practices, Article 28 facilities, IPAs and small to mega-group private practices.

K&K’s healthcare department represents MDs, DOs, DPMs, DDS, DMDs, DCs, PTs as well as other practitioners. Jennifer operates the healthcare department in conjunction with the other practice areas of law at the firm.

When necessary our litigation, real estate, trust and estates or bankruptcy attorneys are available to assist in matters related to healthcare, issues involving practice break-ups, trademark infringement, breach of contract, etc.

Practitioners contact Jennifer at all stages of practice, from their first employment agreement review and negotiation, their first lease, first partnership agreement, first patient issue, first lawsuit, first HIPAA complaint, first hospital contract, collection issues, audit through partnership structuring, mergers and acquisitions, practice sale, hospital employment or closure and everything in between.

We are here to assist in any and all issues that arise that cannot be easily addressed internally or require third party consultation.

Title:
General Counsel
Advanced Degree(s): BA, JD
LinkedIn: https://www.linkedin.com/in/jennifer-kirschenbaum-1a169a17/

 

 

 

For More Information Visit:  www.f2fhealth.com

 

stayhealthy

contact: maria.dorfner@yahoo.com

Hidden Global Epidemic: Kidney Disease

Raising Awareness: Kidney disease is a “hidden epidemic” affecting more than 850 million people worldwide, renal experts say.

That’s twice the number of diabetics (422 million) and more than 20 times the number of people with cancer (42 million) or HIV/AIDS (36.7 million).

But most people don’t realize that kidney disease is a major health issue.

“It is high time to put the global spread of kidney diseases into focus,” says David Harris and Adeera Levin of the International Society of Nephrology.

Harris is the group’s president and Levin is past president. They note kidney diseases often cause no early symptoms.

And many people aren’t aware of their increased risk for heart problems, infections, hospitalization and kidney failure.

Chronic kidney diseases (ones lasting more than three months) affect 10 percent of men and nearly 12 percent of women around the world.

Up to 10.5 million people need dialysis or a kidney transplant, but many don’t receive these lifesaving treatments due to cost or lack of resources.

In addition, more than 13 million people suffer acute kidney injury. Some will go on to develop chronic kidney disease or kidney failure.

Levin says, “Using all these sources of data, and existing estimates of acute and chronic kidney diseases, we estimate approximately 850 million kidney patients — a number which surely signifies an ‘epidemic’ worldwide.”

Kidneys remove waste products and help balance the volume of fluids and minerals in the body. They also produce a hormone that tells the body to make red blood cells, the researchers explained.

“Even if many patients with damaged kidney function don’t feel ill, they’re at high risk for other health problems,” says Carmine Zoccali, president of the European Renal Association — European Dialysis and Transplant Association.

Heart disease deaths due to chronic kidney disease are high — 1.2 million cardiovascular deaths were attributed to kidney disease in 2013.

“The number of people with kidney diseases is alarmingly high, but the public is not aware of this reality. These patients have outcomes and kidney diseases impose a heavy financial burden on health care budgets,” says Mark Okusa, president of the American Society of Nephrology.

The annual per-patient cost of dialysis is $88,195 in the United States.

Even though you can have no symptoms, here are 10 to look out for, according to the National Kidney Foundation.

While the only way to know for sure if you have kidney disease is to get tested, Dr. Vassalotti shares 10 possible signs you may have kidney disease.

If you’re at risk for kidney disease due to high blood pressure, diabetes, a family history of kidney failure or if you’re older than age 60, it’s important to get tested annually for kidney disease.

Be sure to mention any symptoms you’re experiencing to your healthcare practitioner.

  1. You’re more tired, have less energy or are having trouble concentrating. A severe decrease in kidney function can lead to a buildup of toxins and impurities in the blood. This can cause people to feel tired, weak and can make it hard to concentrate. Another complication of kidney disease is anemia, which can cause weakness and fatigue.sleeping
  2. You’re having trouble sleeping. When the kidneys aren’t filtering properly, toxins stay in the blood rather than leaving the body through the urine. This can make it difficult to sleep. There is also a link between obesity and chronic kidney disease, and sleep apnea is more common in those with chronic kidney disease, compared with the general population.sluggish2
  3. You have dry and itchy skin. Healthy kidneys do many important jobs. They remove wastes and extra fluid from your body, help make red blood cells, help keep bones strong and work to maintain the right amount of minerals in your blood. Dry and itchy skin can be a sign of the mineral and bone disease that often accompanies advanced kidney disease, when the kidneys are no longer able to keep the right balance of minerals and nutrients in your blood.
    itching
  4. You feel the need to urinate more often. If you feel the need to urinate more often, especially at night, this can be a sign of kidney disease. When the kidneys filters are damaged, it can cause an increase in the urge to urinate. Sometimes this can also be a sign of a urinary infection or enlarged prostate in men.lawyersleaving
  5. You see blood in your urine. Healthy kidneys typically keep the blood cells in the body when filtering wastes from the blood to create urine, but when the kidney’s filters have been damaged, these blood cells can start to “leak” out into the urine. In addition to signaling kidney disease, blood in the urine can be indicative of tumors, kidney stones or an infection.openyoureyes
    6. Your urine is foamy. Excessive bubbles in the urine – especially those that require you to flush several times before they go away—indicate protein in the urine. This foam may look like the foam you see when scrambling eggs, as the common protein found in urine, albumin, is the same protein that is found in eggs.

 

healthy
7. You’re experiencing persistent puffiness around your eyes. Protein in the urine is an early sign that the kidneys’ filters have been damaged, allowing protein to leak into the urine. This puffiness around your eyes can be due to the fact that your kidneys are leaking a large amount of protein in the urine, rather than keeping it in the body.

hearteye
8. Your ankles and feet are swollen. Decreased kidney function can lead to sodium retention, causing swelling in your feet and ankles. Swelling in the lower extremities can also be a sign of heart disease, liver disease and chronic leg vein problems.

walkinggeneric
9. You have a poor appetite. This is a very general symptom, but a buildup of toxins resulting from reduced kidney function can be one of the causes.

eating
10. Your muscles are cramping. Electrolyte imbalances can result from impaired kidney function. For example, low calcium levels and poorly controlled phosphorus may contribute to muscle cramping.

walking4

HOW IS KIDNEY DISEASE DETECTED?

Early detection and treatment of chronic kidney disease are the keys to keeping kidney disease from progressing to kidney failure. Some simple tests can be done to detect early kidney disease. They are:

  1. A test for protein in the urine. Albumin to Creatinine Ratio (ACR), estimates the amount of a albumin that is in your urine. An excess amount of protein in your urine may mean your kidney’s filtering units have been damaged by disease. One positive result could be due to fever or heavy exercise, so your doctor will want to confirm your test over several weeks.
  2. A test for blood creatinine. Your doctor should use your results, along with your age, race, gender and other factors, to calculate your glomerular filtration rate (GFR). Your GFR tells how much kidney function you have.

It is especially important that people who have an increased risk for chronic kidney disease have these tests. You may have an increased risk for kidney disease if you:

  • are older
  • have diabetes
  • have high blood pressure
  • have a family member who has chronic kidney disease
  • are an African American, Hispanic American, Asians and Pacific Islander or American Indian.

If you are in one of these groups or think you may have an increased risk for kidney disease, ask your doctor about getting tested.

 maria.dorfner@yahoo.com

Real Deal: No More Needles for Blood Draws

v12Velano Vascular is on a mission to bring compassion to healthcare and make painful blood draws more pleasant for patients.  So far, they’re succeeding. They’ve received their 3rd FDA-clearance to help children and adults who cringe at the sight of needles.

Needlephobia affects 24% of adults and 63% of children.

v17

The Boy Who Cried Wolf may come to mind when we talk about no more needles for blood draws because of ill-fated Theranos.  They’re the overly-hyped biotech start-up currently under federal investigation by the S.E.C. and U.S. Attorney’s office. Patients initially thrilled about no more needles got hoodwinked by fake news.

Meet the Real Deal.

V2

Velano Vascular creates a single-use, disposable device called PIVO.

 

It attaches to a peripheral IV line, in hospital inpatients, allowing for lab quality blood samples to be drawn back through the IV –without requiring venipuncture (needle sticks or drawing blood from central lines) .

 

Many of the questions Therano’s CEO never answered, avoided or even got asked by reporters is welcomed by Velano Vascular’s CEO, Eric Stone, who I interviewed.

v4

WHAT IS PIVO AN ACRONYM FOR?

ERIC STONE, CEO, VELANO VASCULAR:  PIVO derives from “peripheral intravenous catheter,” or PIV, which is a medical term for the standard IV most hospital patients are hooked up to in order to receive intravenous fluids..

WHAT IS PIVO?

STONE: PIVO is a single-use, disposable device that attaches temporarily to an IV line, allowing for needle-free blood draws from this existing line.

HOW DOES IT WORK?

STONE: It enables blood draws to be taken by clinicians from the same intravenous (IV) catheter most hospital patients already have inserted in their arms, instead of poking them again each time they need their blood drawn and instead of accessing larger catheters (Central Venous Catheters) which raise different challenges associated with each time they are accessed.

v18

WHO DOES THIS DEVICE HELP PEOPLE?

STONE:  The device works for any patient with an IV catheter. Of course, children tend to more commonly have an acute fear of needles, so it can make pediatric care less invasive and painful.

There are also an estimated 30% of our hospital inpatients that are classified as DVA (Difficult Venous Access) because of aging, obesity, disease and more.

PIVO helps practitioners capture critical labs from these growing populations of patients who otherwise may take significant time and expense.

STONE: Also, those in hospitals or other inpatient settings, where the average length of stay is almost 5 days in the U.S. require daily or more frequent blood draws. Many of these patients have problematic veins or skin, which requires a lot of poking and prodding to draw blood. PIVO tackles these issues head on.

According to the CDC, an estimated 35M inpatient stays occur in the U.S. alone each year.  So, PIVO is set to  help many millions of Americans, not to mention those inpatients around the world.

HOW IS PIVO MORE COMFORTABLE & LESS DANGEROUS FOR PATIENT?

STONE:  For patients who have their blood drawn for a check-up once a year in an outpatient setting, blood draws are not that disruptive.  For a “frequent flyer” in the hospital, or a DVA (difficult venous access) patient –noted as such upon admission or who has become DVA after 10 or 20 days in the hospital feeling like a pin cushion –removing the needle from the procedure can have a lifelong impact.

Enabling practitioners to avoid accessing central lines (large, surgically-placed catheters) for blood draws aims to reduce the risks of Central Line Associated Blood Stream Infection.

Further, removing the needle from blood draws helps avoid risk of injury and infection for our phlebotomists, nurses and physicians. Hospital leadership is recognizing that an important alternative to a prevalent practice is now available.

IF I GET BLOOD WORK FROM AN ANNUAL PHYSICAL WILL THEY USE PIVO?

STONE:  PIVO requires a Peripheral IV catheter in order to access the vein. The IV line serves as a temporary conduit to the vein, so without the IV line PIVO cannot access the vein.

The IV line serves as a temporary conduit to the vein, so without the IV line, PIVO cannot access a patient’s blood.  As such, this procedure is most appropriate for the hospital inpatient setting.

I do envision PIVO will adopted in other care settings, where patients possess an IV line and require frequent blood draws, but the annual physical unfortunately is not one of these.

WHY AREN’T IV’S GOOD FOR DRAWING BLOOD WITHOUT PIVO?

STONE:  IV’s are essentially plastic  tubes which overtime become soft, like a noodle. While a noodle is fine for injecting fluids and medications into a patient, its soft walls collapse under the negative pressure of suction when you try to take fluids out.

There are other reasons why IV’s are less-than-optimal for drawing blood back, but these are quite complex in nature and we’re only just now uncovering some of the novel reasons through our research with leading clinical collaborators.

PIVO simply inserts a small, stiffer tube inside the existing IV tube for the purpose of drawing blood.

It works by propping open and unkinking the IV tube temporarily while enabling lab quality blood be collected.

HOW WAS THE IDEA FOR PIVO ORIGINALLY DEVELOPED?

kidneyblog23

STONE:   Velano’s co-founder and physician, Pitamber Devgon had an elderly patient with bruises up and down her arms from repeated needle sticks.  That patient asked him why he was continually sticking her with needles when she already had an IV catheter in her vein. He didn’t know, but began exploring if it was possible to draw lab quality samples out of the IV line using a separate device.

Stone, a Wharton MBA shares, “Most of my career has been in healthcare, plus I am a needle phobic following my childhood diagnosis with Crohn’s disease as a teenager. So, when I was looking for a company start and a product to bring to market and my former graduate school classmates introduced us, I was instantly engaged following years as a serial healthcare entrepreneur and patient advocate.  From that connection,  Velano was born. “

Velano first won FDA approval for PIVO in 2015, and has also obtained multiple U.S. and international patents for it, with additional applications outstanding in the U.S. & abroad.

v4

STONE: “Five years from now,” asserts Stone, “I believe, without a doubt that PIVO will be the standard of care for inpatient blood draws and vascular access.”

Thanks for a great interview and innovation for healthcare consumers! -Maria Dorfner

http://velanovascular.com

 

MEDIA:   Contact: Michael Azzano at 415-596-1978 to set up telephone or on-camera interviews with patients or Eric Stone, CEO, Velano Vascular.

velano

____________________________________________________

RELATED NEWS:

 

A year ago, Forbes contributor Robert Reiss called Eric Stone “The Steve Jobs of Drawing Blood” and tested PIVO himself.  Reprint of article below courtesy of Reiss.

The Steve Jobs Of Drawing Blood

by Robert Reiss , FORBES CONTRIBUTOR (specializing in writing about CEOs)

Opinions expressed by Forbes Contributors are their own.

I was recently at a board meeting at Griffin Hospital and our CEO was telling us about a new product that could transform perhaps the most ubiquitous healthcare practice – drawing blood.

The concept from a company called Velano Vascular repurposes the IV most hospital patients already have in their arms so blood can be drawn without having their veins repeatedly stuck by needles.

It aims to eliminate the associated negatives of traditional blood drawing: the pain and anxiety, injuries, excessive time and cost.

It seemed like such a revolutionary solution to a broad issue – sort of like in 1892 when Keds invented sneakers – and I was curious to understand if this was truly an historic moment where the age old process of drawing blood could once and for all be revolutionized.

It reminded me of one of my first CEO interviews back in 2007 with Jay Walker, the founder of Priceline when he described the driving force behind one of his over 700 patents, “The key to successful innovation is having a better solution for something that’s used everywhere and every day.”

So I decided to experience this innovation firsthand and a few weeks later I intentionally became a patient and experienced this new needleless way to draw numerous samples of blood.

I was amazed, the nurses were able to draw blood easily, and to do so as many times as they wanted without ever having to stick a needle in me again.

I was next introduced to the founder of Velano Vascular, Eric Stone, who I now admiringly call the Steve Jobs of drawing blood, and below are a few insights from our conversation:

Robert Reiss: How much blood is currently being drawn and what are the problems with the current system?

Eric Stone: Blood draws are not fun – and they are overlooked and underappreciated…except by patients. They are likely the most common invasive medical procedure, with an estimated half a billion in U.S. hospitals alone conducted every year, and two to three times this number across all hospitals worldwide annually.

Recognizing that the U.S. represents nearly 40 million inpatient admissions annually, with an average length of stay of five days, and a conservative estimate of two blood draws per patient per day, we are easily conducting hundreds of millions of inpatient draws each year quite readily.

This does not even take into account other non-hospital settings where patients require regular blood draws, such as long-term care facilities, skilled nursing homes and more – all locations where patients may have a peripheral IV (PIV) catheter indwelling (a requirement for our innovation to be relevant).

For a procedure that informs nearly 70% of all clinical decisions, it is remarkable that the last major innovation was the abandonment of bloodletting centuries ago.

Whether you’re the parent of a sick child or the son or daughter of an elderly parent, repeat hospitalizations and frequent blood draws hit home for just about everyone. It’s scary, it hurts, and it’s critical that we begin to pay attention and stop taking the steely reserve of our patients for granted.

Herein lies the rub. People scared of needles (trypanophobia) avoid necessary tests and treatment, needles injure healthcare workers more than 2 million times a year in accidents that can lead to serious infection, and the list of dysfunction goes on.

The way we draw blood today has real emotional, clinical and financial consequences. We can, and we must, do better. We can start by paying attention.

Reiss: What specifically is different about the Velano Vascular product?

Stone: Velano’s FDA-approved PIVO™ is a disposable, needle free device that connects to a patient’s existing IV catheter, enabling blood draws during their entire hospital stay without requiring subsequent needle sticks.

It turns out that IVs are great at putting fluids into the body but unreliable at pulling them out – that’s why patients receive so many needle sticks while in the hospital.

PIVO turns the routine IV into a reliable conduit for drawing high quality blood samples. This is an elegant solution to a centuries-old problem.

Now, patients no longer need to feel like a “pin cushions” or experience abrupt awakenings between 2:00 am and 6:00 am for the nighttime needle stick – when 40% of blood draws occur.

The company was founded based on a simple idea back in 2012, and subsequently PIVO has been used in clinical pilots and trials at a number of leading U.S. hospitals since receiving regulatory clearance in early 2015.

It has won a number of awards, including the Frost & Sullivan New Product Innovation Award for Vascular Access in 2016 and the Sheikh Zayed Institute for Pediatric Surgical Innovation competition at Children’s National Health in Washington, DC.

Reiss: What are the strengths and weaknesses of your methodology on quality outcomes?

Stone: Velano is most often measured by the clinical quality of blood samples drawn and its impact on both practitioner and patient experience.

In thousands of patients, the quality of our blood samples has been definitive and easy to measure, both through clinical studies and “real world,” commercial use.

Blood drawn from PIVO has similarly low hemolysis rates (blood cell shearing or tearing that can relegate a patient to a re-draw and delays in essential care) to needle draws.

Clinical study efforts and pilots with some of the country’s leading healthcare institutions such as University Hospitals Cleveland, Intermountain Healthcare, The University of Pennsylvania Hospital and Harvard’s Brigham and Women’s Hospital reflect clinically appropriate laboratory results – confirming that blood drawn with our compassionate technology can become a standard of care for clinical decision-making.

Practitioner and patient experience is harder to quantify, but our surveys and testimonials to-date are resoundingly positive. In fact, patients who receive PIVO draws are requesting PIVO when transferred to floors in the hospital that are not participating in our pilots or upon readmission to the hospital. They are actually asking for the product – it is remarkable.

The onus is on Velano to continue improving our quality measurements to undeniably prove this innovation is truly a win-win-win, as we seek to elevate the quality of care and outcomes for patients, practitioners and hospitals alike.

Reiss: What is the financial model for a user and what is the economic impact nationally?

Stone: The cost of a blood draw is not just the $1 or less spent for a needle. Instead, it is the many billions of dollars a year spent on wasted materials, rejected blood samples, patient and practitioner risks, delayed results, labor costs, central line escalations, and more resulting from this less-than-desirable and madly inefficient procedure.

Some of the financial downsides of traditional blood draw standards are somewhat obscure, however we’ve helped our hospital partners understand the current impact by simply asking sincere questions, seeking to learn, and paying a modicum of attention to the topic.

Think about the blood draw on an elderly or obese or diabetic patient that can take as long as an hour of a nurse’s time and 2-3 needles to find a vein and collect an adequate sample.

Consider that even one single case of an employee blood borne pathogen transmission from a needle stick can cost millions of dollars in exposure for a hospital.

For PIVO, we understand that in an environment of increasing health industry price transparency and pressures, when our entire healthcare system is experiencing economic upheaval, and cost neutrality is required for rolling out true innovation in hospitals.

 

Reiss: Why did you start Velano Vascular and what’s your vision?

Stone: The reason why is very simple – because I am first and foremost a patient, and I am a parent.   25 years ago I was diagnosed with Crohn’s disease, launching me on a lifelong journey as a healthcare entrepreneur, patient advocate, and National Trustee of the Crohn’s and Colitis Foundation of America. Since a young age, I’ve been motivated by IMPACT.

I started Velano in partnership with an intellectually curious physician inventor intrigued by a seemingly simple question posed by his patient – “why are you repeatedly sticking me with needles [when I already have an IV line in my arm]?”

This simple, yet elegant idea resonated strongly with me, for I am needle-phobic myself, and I have been that “tough stick” patient during my hospital stays. Today, this brilliant idea has become reality.

My vision for Velano is to touch every human being on the planet; for we will all spend time in a hospital at some point in life, and we will certainly need our blood drawn when we do.

 

http://velanovascular.com

 

MEDIA:   Contact: Michael Azzano at 415-596-1978 to set up telephone or on-camera interviews with patients or Eric Stone, CEO of Velano Vascular

logonewsmd

Maria Dorfner founder of NewsMD: What’s Hot in Health

abc2

NewsMD Communications was founded in 1998 to educate healthcare consumers by connecting medical + media to inspire and empower millions to want to live healthy.

In 1993, Maria created Healthcare Consumers, Healthy Living, Lifestyles & Longevity and Healthcare Practitioners. The shows aired on CNBC, which she helped launch in 1989.  She is the founder of Cleveland Clinic News Service, helped launch MedPage Today (sold to CNN) and wrote & produced 21st Century Medicine for Discovery Health.  Her awards include Freddie for Excellence in Medical Reporting, Outstanding Leadership Abilities, Media Recognition, Who’s Who, Medical Reporting Scholarship. She produced for Journal of the American Medical Association (JAMA) Report, talk shows & reality programming.

She began as an intern at NBC todaylogo SHOW in NYC in 1983.

This is her blog.

Have an innovative solution healthcare consumers|media should know about?

Contact: maria.dorfner@yahoo.com  

Response only if it’s a story of interest. Thank you.

gmalogodiscoverylogo2 cnbclogo

nbclogo4  abclogo cbslogo1nbc1cnn foxlogo

cbslogo  nbclogo2

todaylogo

Breakthrough: Mi-Eye2 Diagnoses Joint Injuries With Tiny Camera

TRICE MEDICAL closes $19.3M in Series C financing for their tiny needle-based camera to analyze joint injuries and expedite orthopedic diagnosis without the need for an MRI.

mieye2

Mi-Eye2 is a hand-held imaging scope which received FDA-clearance.  It enables doctors to diagnose a sports-related injury in the office, without an MRI.

mieye

It consists of a hypodermic needle with a small camera tethered to a Microsoft surface tablet that shows high-definition pictures.

 

trice11

Jeffrey O’Donnell, Sr. who is President and CEO of Trice Medical says this latest round of financing is a “significant milestone” and will help expand the company’s U.S. market.

Check out CBS2’s Dr. Max Gomez report:

MAXGOMEZ3

CBS 2’s DR. MAX GOMEZ: If you’ve ever injured your knee it can be hard to tell exactly what’s causing the pain, so the doctor usually sends you for an expensive MRI and maybe an arthroscopy in the O.R. to take a look inside. But what if you could do a scope in the doctor’s office cheaper and safer.

Lemouchi Soufinae injured his knee in a car accident two years ago. Since then he hasn’t been able to play his beloved soccer, because of the pain in his knee.

“I can’t walk more than three blocks, have to lay down, have trouble sleeping at night, lot of strong pain,” he said.

DR. MAX GOMEZ: Two MRIs later, it still wasn’t completely clear what was causing his knee pain.

Lemouchi, Liz Meris has been having severe knee pain. “I couldn’t kneel or straighten without pain, can’t get out of car, swelling in back of knee, hurts to walk, feels unstable,” she said.

DR. MAX GOMEZ: Worse yet, Liz is claustrophobic in an MRI.

“I hate em, I’m claustrophobic. I’m out, I’m in, I’m out again,” she said.

DR. MAX GOMEZ:  The next is usually a trip into the operation room to look around by sticking a scope in the knee. It’s expensive and requires anesthesia. Why not do that in the office, under a local anesthesia?

Thanks to a tiny scope with a hi-def camera on the tip, doctors can do in the office what once took a trip to the O.R.

“It’s a huge game changer, been trying to do for 10 to 15 years, clarity and resolution are now tremendous,” Dr. James Gladstone, Mt. Sinai Health System said.

DR. MAX GOMEZ:  Using only a local anesthesia, Dr. Gladstone inserts the MI-Eye-2™ into Liz’s knee. She was actually watching the same thing Dr. Gladstone was seeing.

It allows him to check and see what and where there’s damage inside the knee.

“Almost as good as O.R. scope, and in many ways better than MRI because it can give you direct visualization,” Dr. Gladstone said.

DR. MAX GOMEZ:  Better yet, if the damage is minimal it saves the patient a trip to the O.R. for a conventional scope, and here’s the best part; it costs under $500 to do this in the doctor’s office as opposed to the $1,500 or $2,000 for an MRI and thousands more for an O.R. scope.

Almost any joint that you can scope can be done with the MI-Eye™: shoulder, wrist, ankle, elbow.

mieye

FOR MORE INFORMATION on THE INNOVATIVE MI-EYE2 VISIT:

http://www.tricemedical.com

 

Also, check out Dr. Max Gomez’s new book available for preorder on Amazon:

“Cells Are the New Cure”

by Robin Smith, MD + Max Gomez, Ph,D; Foreword by Sanjay Gupta, MD of CNN

https://www.amazon.com/Cells-Are-New-Drugs-Bre…/…/1944648801

maxgomezbook

 

mariadorfnerheadshot2
Maria Dorfner, a 33 year veteran of broadcast news is the founder of this blog.

Contact:  maria.dorfner@yahoo.com

healthnewslogo

 

Future Health: New Device To Detect Early-Stage Colon Cancer

DANIELA SEMEDO reports on a European project, which aims to develop an innovative endoscope device that can detect and diagnose colorectal cancer in its early stages.

coloncancer2

Called PICCOLO, the project is funded under the European Union’s Horizon 2020 program. It’s tackling one of the world’s predominant cancers by using new optical technologies that identify precancerous polyps and early colon cancers.

coloncancer1

Colorectal cancer represents around one-tenth of all cancers worldwide, and nearly 95 percent of these cases are adenocarcinomas, which typically start as a tissue growth called a polyp.

coloncancer4

Early and accurate diagnosis and precise intervention can increase cure rates to up to 90 percent.

coloncancer3

A colonoscopy is currently the method used to screen for colon cancer. But while up to 40 percent of patients who undergo colonoscopy present one or more polyps, almost 30 percent of these polyps are not detected.

coloncancer6

Of the polyps detected by colonoscopy, 29 to 42 percent are generally hyperplastic and will not develop into cancer. The remainder are neoplastic polyps, representing colorectal cancer in its earliest stages.

There is an urgent need for new diagnostic techniques that are equipped with enough sensitivity and specificity to allow in situ assessment, safe characterization, and resection of lesions during clinical practice interventions.

colon9

The multidisciplinary PICCOLO team proposes a new compact, hybrid, and multimodal photonics endoscope based on Optical C, a medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media.

Artzai Picon of Tecnalia Research & Innovation says, “We hope that PICCOLO will provide major benefits over traditional colonoscopy. Firstly, by developing an advanced endoscope, using both optical coherence tomography (OCT) and multi-photon tomography (MPT), we will provide high-resolution structural and functional imaging, giving details of the changes occurring at the cellular level comparable to those obtained using traditional histological techniques.”

“Furthermore, when multiple polyps are detected in a patient, the current gold standard procedure is to remove all of them, followed by microscopic tissue analysis,” he said. “Removal of hyperplastic polyps, which carry no malignant potential, and the subsequent costly histopathological analysis, might be avoided through the use of the PICCOLO endoscope probe, which could allow image-based diagnosis without the need for tissue biopsies.”

Researchers behind the project believe the new device may not only add to colon cancer detection, but could also be applied to diseases in other organs of the body.

coloncancer7

Investigators expect their first prototype to be fully developed by the end of 2018 and plan to start testing the device in clinical studies in 2020.

colon7

DANIELA SEMEDO, Colon Cancer News
https://coloncancernewstoday.com/2017/06/08/bristol-myers-squibb-novartis-to-test-mekinist-opdivo-combination-in-advanced-colorectal-cancer/

colon4

 

http://www.fightcolorectalcancer.org

 

Maria Dorfner is the founder of NewsMD: What’s Hot in Health, a division of Healthy Within Network.  Have a story to share with healthcare consumers and media?

Contact: maria.dorfner@yahoo.com

 

GAME CHANGER: NEW SMART HEART MONITOR

 

Super excited to tell you about a new smart heart monitor you can use at home. It will help 28 million heart disease patients in the U.S. keep track of their heart.

eko5

Keep track from the comfort of their home at any time. And it’s just been FDA approved.

eko4

Meet Eko DUO.  The first handheld mobile, wireless, EHR-connected stethoscope, which connects to your smart phone.

It allows you to amplify, visualize and record crystal clear heart and lung sounds.

Imagine not needing to wait for your next followup appointment to transmit a concern to your physician. It works under the supervision or prescription from a physician.

eko3

Eko Duo is set to help millions of heart disease patients who are often discharged with little more than an info packet and instructions to monitor their weight.

eko9

Now patients can be sent home from the hospital with a direct link back to their physician, helping reduce readmissions and false alarms.

“The goal is to bring hospital-quality care to the home.”
Connor Landgraf, CEO and co-founder, Eko DUO

The device wirelessly pairs with Eko’s secure, HIPAA-compliant app, enabling remote monitoring and diagnosis by a clinician or specialist.

It works with the Eko app on any iPhone, iPad, Windows PC or Android device.

eko8

Eko DUO can also be used by clinicians as an enhanced stethoscope for in-clinic cardiac screenings, enabling physicians to quickly diagnose and monitor patients.

Clinicians can use it bedside or remotely to quickly spot heart abnormalities including arrhythmias, heart murmurs, and valvular heart diseases.

I interviewed Ami Bhatt, M.D., a Cardiologist at Massachusetts General Hospital and Director of Outpatient Cardiology and the Adult Congenital Heart Disease Program at Massachusetts General Hospital and she believes Eko DUO will improve outcomes through early intervention.

DrAmiBhattHeadshot

Dr. Bhatt says, “Cardiology programs are looking for ways to deliver hospital-quality healthcare at home.  The ability to capture digital heart sounds and an ECG expands our portfolio of mechanisms to remotely monitor the heart – and brings diagnosis and opportunities for early intervention even further upstream.” 

Heart disease can strike people of all ages.

I spoke with Stacy Bingham, a registered nurse from Oregon with 5 children, who knows this firsthand. She and her husband have no prior history of heart disease in their family, yet 3 of her 5 children end up needing heart transplants.

Stacy_Bingham_and_Family

When Stacy noticed her oldest child, Sierra acting tired with a loss of appetite for a few weeks, she never suspected the cause was an underlying heart condition.

“I noticed her face and eyes were swollen. She complained her stomach hurt.”

That’s when Stacy and her husband took her to a family practitioner.

“The doctor told us it’s probably a flu bug and sent us home. When her condition worsened she had an x-ray.”

X-ray results revealed Sierra’s heart was enlarged.  Dilated cardio myopathy. She later learned two of her other children also had heart problems.

“If they had not finally found Sierra’s heart condition, she may not have survived. We live in a really rural part of Eastern Oregon and we now have three kids with heart transplants that need to be monitored for life.”

Today, Stacy’s family takes nothing for granted, especially innovations that help.

“If this device can be used at home and we can rule out scary things and know when it’s not something we need to rush to a hospital for that would be wonderful.” –Stacy Bingham

James Young also knows how life can change in a heartbeat.

James-Young_headshot

Young was just 40-years-old when he first experienced symptoms of heart failure. Symptoms he ignored until they were severe and his sister insisted on it.

“I was coughing in mornings and throughout the day. I thought it was simply allergies. I vomited phlegm some mornings and still didn’t see a doctor.”

But the coughing became more painful. While shoveling, it stopped him in his tracks.

“I was outside shoveling snow when I turn behind me and  see a trail of blood.”

His sister noticed he didn’t look well and insisted he go see a physician.

“That’s when I was diagnosed with congestive heart failure. I was shocked.”

James felt anxiety, depression and uncertainty about his future at this time. Young believes Eko DUO will not only help alleviate false alarms and unnecessary hospital readmissions, but needless worrying as well.

DUO_and_App_

 

“Eko DUO would have given me assurance the doctor knew where I stood daily. If there were any issues outstanding needing to be addressed immediately. It gives the doctor an opportunity to respond expeditiously to those concerns.”

Today, James is doing great and is a national spokesperson and heart failure Ambassador for the American Heart Association.

JamesYoung

“I went from a 25% functioning heart to being an avid runner and cycler. I’ve taken on a new lease in life. As a community advocate I can help inspire others and give them hope.”

Ami Bhatt, M.D says that hope also translates to much needed continuous care rather than outpatient care.

“Robust toolkits for caring for patients in the community will hopefully lead to more appropriate healthcare utilization through continuous rather than episodic outpatient care.”

HERE’S HOW EKO WAS DEVELOPED:

Eko’s co-founder & CEO, Connor Landgraf, is also a heart disease patient.

eko14

Connor navigated countless cardiology visits, screenings and referrals.

eko13

In 2013, during his senior year as at the University of California at Berkeley, Connor attended a panel discussion at UC San Francisco on technological shortcomings facing modern medical practices.

One technical gap cardiologists claimed stood out beyond the rest: the stethoscope.

doctor1

So Conner and his co-founders welcomed the stethoscope, a two-century old tool, into the 21st-century.

eko12
Photo: Connor and his co-founders, Jason Bellet and Tyler Crouch

 

The newly FDA approved Eko DUO brings that to the next level.
DUO_and_App_

 

To learn more about this remarkable 21st Century technology we love visit:  http://www.ekodevices.com

 

 

Factoids:

  • According to the CDC, heart disease is the leading cause of death in the U.S.
    The American Heart Associations says the U.S. currently spends over $26 billion annually on heart failure hospitalization. 25% of heart failure patients are readmitted within 30 days — 50% are readmitted in 6 months with hospitals now being penalized for high readmission rates.
    ________________________________________________________________________________
  • Fact: 83% of parents experience anxiety surrounding their child’s referral to a pediatric cardiologist for an innocent murmur.
    _________________________________________________________________________________
  • Fact: Average cash price for an echocardiogram is $2,275 and even with insurance, patients can expect to pay 10 to 30% of this cost.
    _________________________________________________________________________________
  • Fact: For a pediatric subspecialist such as a pediatric cardiologist, patients must wait between 5 weeks and 3 months to get an appointment.
    _________________________________________________________________________________
  • Fact: Internal medicine residents misdiagnose more than 75% of cardiac events.
    _________________________________________________________________________________
  • Fact: 70% of all pediatric cardiac referrals for murmurs are unnecessary.
    _________________________________________________________________________________
  • Fact: Average PCP needs to coordinate care with 99 other physicians working across 53 practices.
    _________________________________________________________________________________
  • Fact: Only 50% of initial referrals are accompanied by information from the PCP.
    _________________________________________________________________________________
  • Fact: Patients in rural communities must travel an average of 56 miles to see a specialist.
    _________________________________________________________________________________
  • Fact: About 46.2 million people, or 15% of the U.S. population, reside in rural counties.

Eko_in_Haiti

 

eko5

Eko DUO.  A real game changer for heart patients worldwide.

http://www.ekodevices.com

 

 

Expert Newborn Screenings A Heartbeat Away!

jimmy-kimmel-baby-billy2-1This week, Jimmy Kimmel shared the emotional story of his beautiful newborn son’s heart surgery.  He and his wife Molly welcomed their second child, William “Billy” Kimmel.

At three days old, Billy had successful open heart surgery at Children’s Hospital Los Angeles and is now home with his family.  On his show, Jimmy opened up about his son’s birth and health complications. He also underscored the need for the accurate and timely screening of congenital heart disease (CHD).

heart4

Essential to early CHD diagnosis is the detection of a murmur using a stethoscope during a newborn’s first physical exam.

heart5

But routine neonatal examination without specialist consults fail to detect more than half of babies with heart disease.

Approximately 160 infants pass away from undetected Congenital Heart Defects each year in the United States.

William “Billy” Kimmel, who is absolutely adorable below is one of the lucky ones; looks like he’s already laughing at Dad’s jokes too.

jimmyrs_600x600-140722042640-600.Jimmy-Kimmel-Baby-Jane-JR3-72214

Billy thankfully had the condition detected early, but many children with CHD get discharged with undetected or misdiagnosed conditions.

jimmy-kimmel-new-baby-heart-surgery-20170502.png

After the events of this week, expecting parents have every right to question if their child is being screened appropriately or if clinicians known to misinterpret heart sounds are interpreting their child’s heart sounds accurately.

Kimmel’s story is really a wake-up call that we need more nurses like the wonderful ones who treated his baby boy.

doctor3

Now, there’s a device that will make sure congenital heart screenings more effective for infants.

heart3

 

And it’s not just infants. Over 1.3 million adults live with congenital heart disease in the U.S, which now surpasses the number of children with congenital heart disease.

walking2

Three entrepreneurs are well on their way to making sure accurate screenings are a heartbeat away. Their innovation paves the way for a new era of cardiac screenings.

They want to do what Shazam did for music, only for heartbeats.

Their new device called Eko [pronounced like Echo, as in a heart echo] offers the potential to dramatically improve the efficacy of newborn screenings, especially for newborns far from a pediatric cardiology center.

Eko_Product_Suite

The San Francisco based digital medical device company, launched Eko, an FDA-cleared digital stethoscope that enables ANY clinician, regardless of their training level, to secure a virtual pediatric cardiology opinion on heart sounds recorded with their FDA-cleared digital stethoscope.

It was a pleasure interviewing one of the founders, Jason Bellet.

Bellet says, “The silver lining in Jimmy Kimmel’s story is that the congenital heart failure was detected early through a murmur using a stethoscope and could be treated, but very often these murmurs go undiagnosed and undetected and infants leave the hospital with potentially life threatening situations.” [:27]

“Eko Devices would enable nurses and clinicians to get Cardiologist’s second opinion to immediately decrease the number of missed cases.” [:12]

Bellet is the co-founder and a brilliant former student from the University of Berkley.  He graduated in 2014 and founded Eko Devices with two fellow students, Connor Landgraf and Tyler Crouch out of the Start-up accelerator at Berkley.

The three founders successfully pitched their idea and raised $5M to bring it to market quickly and bring it to as many clinicians as they can.  It received FDA approval in September of 2015.

QUESTION: WHAT IS EKO?

ANSWER:  It’s basically a Smart Stethoscope that can bring the sounds to a trained ear immediately.

The vision is to bring machine learning and physician support tools to every clinicians stethoscope to make their screening process as easy as Shazaming a song.

QUESTION:  HOW DID YOU COME UP WITH THE IDEA FOR EKO?

ANSWER:  The idea stemmed from the fact that we realized the stethoscope is used as the primary screening tool for cardiac health, including for newborn babies.

But, it’s extremely outdated and ultimately leading to misdiagnosis and lack of cardiac conditions because you hear the heart sounds, but don’t understand what you’re hearing.

Cardiologists are the ones who can differentiate what is normal and what is not.

So, what we wanted to do was make it easy for clinicians to modernize their own stethoscopes to bring it into the modern era and send concerning or confusing heart sounds immediately to cardiologists in real time using this platform or capture it to send it to a specialist.

QUESTION:  There are other digital stethoscopes out there. Why is this one unique?

Bellet says, “Our digital stethoscope is the first to allow clinicians to stream sounds wirelessly from the stethoscope to a smartphone and to a cardiologist anywhere in the world.”  [:15]

QUESTION: Is it HIPPA compliant?

ANSWER:  It’s the ONLY digital stethoscope on the market that has built a HIPPA compliant software platform to stream heart sounds from any clinician to any specialist anywhere in the world.

Eko_in_Haiti

QUESTION: THAT’S GROUNDBREAKING. WHERE IS IT CURRENTLY BEING USED?

ANSWER:  Eko is now used at over 700 institutions across the country and has been adopted by pediatric cardiology programs.

QUESTION: WHO NEEDS EKO?

The technology is applicable in many aspects of patient care, but especially in newborns.

QUESTION:  WHAT IS YOUR ULTIMATE GOAL WITH EKO?

ANSWER: The ultimate goal is bringing it even one step further.  Our idea is have machine learning tied directly into the stethoscope itself, so one day clinicians can be as accurate as cardiologists in their initial interpretation of what they hear.

______________________________________________________________________________________

DrAmiBhattHeadshot

Next, I spoke with renown adult congenital heart disease specialist Ami Bhatt, M.D. F.A.C.C. who says identifying congenital heart disease in the community can be challenging at any age whether we are trying to identify a high risk newborn like Jimmy Kimmel’s or catching congenital heart disease in a school age student or adulthood.

Ami Bhatt, M.D. F.A.C.C.  is director of outpatient cardiology at the Massachusetts General Hospital in Boston as well as a renown adult congenital heart disease specialist.  She innovates with the Healthcare Transformation Lab, serves as a scientific advisor for Eko Devises and runs a telemedicine practice.  She can be reached at mghachd@partners.org

Bhatt says,  “Because congenital heart disease is relatively rare it’s difficult for clinicians to identify it. The use of digital stethoscopes and other telemedicine technology which can connect the patient and caregiver in the community with experts at academic centers can improve initial diagnosis AND longterm followup.”

QUESTION:  WHAT HAPPENS WHEN KIDS WITH CONGENITAL HEART DISEASE AGE?

ANSWER:   Two things. One, as kids with congenital heart disease age, we know there are complications that may arise. Technologies like digital stethoscopes and the use of algorithms can help monitor their progression and track changes in disease BEFORE they progress too far.

And two, lack of follow-up is a persistent problem with children with congenital heart disease become adults. One of the main drivers is the challenge of access to subspecialty care.

Additionally, distance from medical centers, along with the time it takes and sometimes the cost of being away from work and family drives young adults to ignore their own healthcare needs.

The advent of digital health in congenital heart disease care empowers the patient to engage in a partnership to their health without taking away from their ability to live a full and active life.

QUESTION:  DO YOU THINK TECHNOLOGY HELPS OR HINDERS DOCTOR-PATIENT RELATIONS?

ANSWER: As the delivery of healthcare changes, caregivers are desperate to return to the ideal  doctor patient relationship, which is based on a human connection. As we build digital technology, and use machine learning to support our physicians at at time when there are so many diagnosis to be made, it allows us to concentrate on a shared patient and provider centered experience.

QUESTION:  HOW DOES AN ADULT KNOW WHEN TO GET THEIR HEART CHECKED?

ANSWER: If they had heart disease or heart surgery as a child, they should check in with their cardiologist to find out if they need any longterm care.

QUESTION: HOW DO THEY FIND A SPECIALIST?

There are advocacy websites, such http://www.ACHAheart.org which report self-identified Specialists in congenital heart disease or they can call a major center like Massachusetts General who can find a local center that can partner in their care.

QUESTION: HOW CAN THEY FIND OUT WHO USES THE EKO DEVICE?

ANSWER: If they want to find a specialist using the Eko Device people can contact Massachusetts General http://www.massgeneral.org\adultcongenitalheart for more information and ask about centers near them. They can also contact any hospital and ask for their telemedicine department and inquire if they use Eko.

QUESTION: HOW DO CLINICANS FIND EKO IF THEY’RE INTERESTED IN USING IT?

ANSWER:  Clinicians are able to access the device by going to the Eko Devices website at http://www.ekodevices.com and then if they’re interested in testing it they can purchase a unit directly from the website and send it back if they don’t like it. But that’s a rarity as the success rate has been high with over 5,000 clinicians across the country using it.

Eko_Product_Suite.png

This truly is a hot technology that will save kids like Jimmy’s, as well as those who aren’t at top hospitals in the country.

Billy will have another open-heart surgery within six months to repair the hole, and Our thoughts, well wishes and prayers are with him and his family.

“As a cardiologist, we sometimes worry about technology interfering with the doctor patient relationship. However, in these cases, it is technology that brings us to meet the patient where they live. Technology is finally bringing us home.” 

-Ami Bhatt, M.D. F.A.C.C.

If you haven’t seen Jimmy Kimmel’s story see it on Emmy-award-winning @GMA:

WATCH: @jimmykimmel shares emotional news about newborn son’s emergency heart surgery; son now at home recovering. http://abcn.ws/2pSPakE

gmalogo

QUICK FACTS:

According to the CDC, 40,000 babies in the U.S. are born each year with congenital heart disease.

Recent studies estimate approximately 160 infants or 1 in 25,000 live births die per year from unrecognized CHD.

The reported sensitivity for detection of a pathologic heart murmur in newborns ranges from 80.5 to 94.9 percent among pediatric cardiologists, with specificity ranging from 25 to 92 percent.

A study in the American Journal of Medicine discovered internal medicine residents misdiagnose as many as 75% of murmurs with a stethoscope.

Routine neonatal examination fails to detect more than half of babies with heart disease; examination at 6 weeks misses one third.

A normal examination does not exclude heart disease.

Babies with murmurs at neonatal or 6 week examinations should be referred for early pediatric cardiological evaluation which will result either in a definitive diagnosis of congenital heart disease or in authoritative reassurance of normal cardiac anatomy and function.

heart4

Take care of your heart everyone!

 

For more on Eko visit: http://www.ekodevices.com

UPDATES:

Good Morning America
ABC NEWS
May 9, 2017
Jimmy Kimmel returns to TV with update on his son’s health, defends his call for children’s health care coverage

One week after Jimmy Kimmel revealed that his son, Billy, had been born with a heart defect, the comedian returned to host his late night show with an emotional update on his son’s health and a defense of his foray into the country’s heated debate on health care.

The “Jimmy Kimmel Live!” also thanked his fans for their “humbling outpouring of support” and said that he and his wire “very grateful” for the multitude of donations made to the Children’s Hospital of Los Angeles, where his son was treated.

“First I want to tell you because so many people have asked: Our son Billy is doing very well,” Kimmel said. “He’s eating. He is getting bigger. He is sleeping well. He can read now — which they say is unusual [for a child his age].”

Kimmel, 49, revealed last Monday that his son underwent surgery on his heart three days after he was born, and will require another procedure when he’s a little bigger in three to six months.

During his monologue, Kimmel asked all politicians to come together to ensure healthcare for all Americans, especially those who have pre-existing health conditions.

Though there were many who supported Kimmel’s point of view, he noted that there were many others who called him an “out of touch Hollywood elitist.” To those critics, the late night host offered a sarcastic apology.

“I’d like to apologize for saying that children in America should have health care,” he joked. “It was insensitive – it was offensive – and I hope you can find it in your heart to forgive me.”

To further the conversation, he interviewed Bill Cassidy, a Republican senator from Louisiana who last week tweeted that there should be a “Kimmel Test” for any healthcare bill passed.

The Jimmy Kimmel Test, he noted, would be in place to ensure that any healthcare plan would adequately cover pre-existing conditions “but in a fiscally conservative way that lowers cost.”

“I happen to like [it] a lot,” Kimmel said. “He is a doctor – a gastroenterologist. He is married to a retired doctor — his wife Laura, was a surgeon. And he co-founded the Greater Baton Rouge Community Clinic, which provides free dental care and health care to the working uninsured. So obviously – this is someone who cares about people’s health.”